Abstract
Background:
Arterial stiffness is an early indicator of atherosclerosis. The blood urea nitrogen to serum albumin ratio(BAR) is associated with poor prognosis in several chronic diseases. However, the relationship between BAR and arterial stiffness in type 2 diabetes mellitus (T2DM) patients has not been extensively studied. This study aimed to examine the relationship between BAR and brachial-ankle pulse wave velocity (baPWV), an indicator of arterial stiffness in patients newly diagnosed with T2DM.
Methods:
A total of 510 adult patients newly diagnosed with T2DM were enrolled between January 2021 and December 2023. BAR was calculated by blood urea nitrogen/albumin ratio. A baPWV ≥1400 cm/s was defined as arterial stiffness. A linear regression model and logistic regression model were used to assess the relationship between BAR and baPWV after adjusting for potential confounders.
Results:
The average age of the patients in this study was 45.66 ± 10.18 years, and 78.8% were male. The mean baPWV was 1469.15 ± 295.82 cm/s, and 50.8% of patients exhibited arterial stiffness. The prevalence of arterial stiffness increased significantly across ascending BAR tertiles (T1: 39.3%, T2: 51.7%, T3: 61.4%; p = 0.002). Linear correlation analysis revealed a positive correlation between BAR and baPWV. According to the fully adjusted logistic regression model, each unit increase in the lnBAR was associated with a 3.452-fold greater risk of arterial stiffness[95% CI(1.586, 7.513), p = 0.002]. Compared to the lowest tertile (T1), participants in the middle (T2) and highest (T3) BAR tertiles had a significantly greater risk of arterial stiffness [T2: OR = 1.915, 95% CI (1.016, 3.609), p = 0.044; T3: OR = 2.064, 95% CI (1.051, 4.054), p = 0.035]. Stratified analyses demonstrated consistent positive correlations between BAR and baPWV across sex and BMI subgroups, as well as in individuals aged < 50 years.
Conclusion:
BAR levels were independently and positively correlated with baPWV in Chinese patients with newly diagnosed T2DM.
1 Introduction
The global diabetes epidemic poses a significant challenge to public health systems worldwide, imposing considerable economic and social burdens. According to the International Diabetes Federation (IDF) (), 589 million adults aged 20–79 years are living with diabetes globally. This number is expected to rise to 853 million by 2050, with over 90% of cases attributed to type 2 diabetes mellitus (T2DM). China has the highest diabetes burden, affecting 12.8% of the adult population (). Crucially, diabetes-related complications, particularly macrovascular diseases such as atherosclerosis, ischemic heart disease, and stroke, have emerged as the leading causes of mortality and disability among patients with diabetes. Importantly, these complications are increasingly prevalent among younger populations (), underscoring the urgent need for early screening of high-risk individuals and implementation of targeted vascular protection strategies.
Arterial stiffness, characterized by diminished arterial elasticity due to structural and functional abnormalities of the arterial wall, represents an early indicator of atherosclerosis (). Substantial evidence indicates that increased arterial stiffness is independently correlated with cardiovascular disease (CVD) and renal impairment, serving as a predictor of cardiovascular morbidity and mortality (–). Diabetes exacerbates arterial stiffening through various pathophysiological mechanisms, including insulin resistance, endothelial dysfunction, non-enzymatic glycation, platelet dysfunction, chronic inflammation, and increased oxidative stress (). In patients with T2DM, early detection of arterial stiffness, in conjunction with biomarker identification, is crucial for mitigating the progression of atherosclerosis. Brachial-ankle pulse wave velocity (baPWV), a noninvasive and cost-effective clinical tool, has a strong ability to predict for cardiovascular risk and all-cause mortality in diabetic patients (, ). Notably, assessing baPWV in newly diagnosed with T2DM is of significant clinical importance. Many of these patients have already experienced prolonged hyperglycemia, which initiates the progression of vascular stiffness. Early detection of arterial stiffness in this population provides a critical opportunity for intervention, potentially altering the progression of CVD.
Blood urea nitrogen (BUN), a metabolic byproduct of protein catabolism, serves as a biomarker of renal function, nutritional status, and volume status. It has also been independently associated with CVD mortality risk, establishing its utility in the assessment of CVD prognosis (, ). Serum albumin(ALB), a key nutritional indicator, critically mediates substance transport, ligand binding, and maintenance of plasma colloid osmotic pressure. Additionally, it has antioxidant, anti-inflammatory, and endothelial stabilizing functions (, ). The blood urea nitrogen to serum albumin ratio (BAR) is an innovative biomarker that combines indicators of BUN and ALB, reflecting both nutritional and inflammatory factors. Studies have demonstrated that it has significant predictive value in assessing the prognosis of various diseases, including pneumonia, chronic heart failure, sepsis, and renal insufficiency (–). However, its association with arterial stiffness in patients with T2DM remains unknown. Therefore, this study aimed to investigate the correlation between BAR and arterial stiffness, as determined by baPWV, in individuals newly diagnosed with T2DM.
2 Methods
2.1 Data source and study population
This was a cross-sectional study. A total of 510 adults with newly diagnosed (< 3 months) with T2DM who were drug-naïve—defined as individuals who had not previously received any treatment with oral hypoglycemic agents or insulin—were enrolled. These patients were under follow-up care at the National Metabolic Management Center (MMC) of Longgang Central Hospital in Shenzhen between January 2021 and December 2023. The MMC is a platform for the standardized diagnosis, management, and follow-up of patients with metabolic diseases. All individuals who met the 1999 WHO diagnostic criteria for T2DM were included in the study. The main exclusion criteria were autoimmune diabetes, secondary diabetes, pregnancy, malignancy, chronic kidney disease (eGFR <60 ml/min), chronic liver disease, coronary artery disease, heart failure, and stroke. The study was conducted in accordance with the principles outlined in the Declaration of Helsinki, and the research protocol received approval from the Ethics Committee of Longgang Central Hospital. Informed consent was obtained from all participants.
2.2 Clinical and laboratory data
Face-to-face interviews were conducted with all patients to obtain relevant information, including age, sex, occupation, medical history, and personal habits such as smoking and drinking. The duration of T2DM was calculated from the time of the first diagnosis. Blood pressure was measured via an automated blood pressure cuff with the participant in a seated position on the upper arm. The average value was derived from three consecutive measurements. The subjects’ height and weight were measured in a fasted state on the morning of the study, and the body mass index(BMI) of each individual was calculated via the following formula: weight (kg)/height (m)². Waist circumference was measured at the midpoint between the lower edge of the lowest rib and the upper edge of the hipbone using a non-elastic flexible ruler. The average of the two measurements was calculated. Plasma was collected from the patients in a fasted state eight hours after their overnight stay, and the following indicators were measured via a fully automated biochemical analyzer: fasting blood glucose, fasting C-peptide, glycosylated hemoglobin(HbA1c), alanine aminotransferase(ALT), aspartate aminotransferase(AST), gamma-glutamyltransferase(GGT), serum albumin(ALB), serum uric acid, creatinine, blood urea nitrogen(BUN), triglyceride(TG), total cholesterol(TC), HDL cholesterol(HDL-C) and LDL cholesterol(LDL-C). The eGFR was calculated from serum creatinine using by abbreviated MDRD study equation [eGFR (mL/min/1.73 m²) = 186 × (Scr)^-1.154 × (Age)^-0.203 × (0.742 if female)] and included as a continuous variable. BAR(mmol/g) was calculated by the ratio of BUN (mmol/L) to albumin(g/L). The patients were divided into three equal groups according to their BAR level:T1, BAR <0.0874; T2, BAR between 0.0874 and 0.1161; and T3, BAR >0.1161.
2.3 Brachial-ankle pulse wave velocity measurement
BaPWV was measured via an automated atherosclerosis testing device (VP-1000; Omron Corporation, Kyoto, Japan). The participants were placed in the supine position and allowed to rest for at least five minutes. Blood pressure cuffs were then attached to the upper arms (brachial arteries) and ankles (posterior tibial arteries) bilaterally. Cardiac leads were also connected to synchronize the pulse waveforms in the cuff arteries. The conduction distance between the arm and ankle was measured, and the conduction time was defined as the interval between the initial rise in the waveforms of the brachial and posterior tibial arteries. The baPWV was calculated by the following formula: baPWV (cm/s) = conduction distance (cm)/conduction time (s). The average baPWV was calculated by averaging the baPWV readings from both sides, and baPWV ≥1400 cm/s was defined as arterial stiffness, as previously reported (, ). All operations were performed by technicians who had received uniform technical training, and measurements with poor waveforms were excluded.
2.4 Statistical analyses
Data that followed a normal distribution are presented as the means ± standard deviations, while data that did not follow a normal distribution are presented as medians with quartile ranges. Count data are presented as frequencies and percentages (n, %). BaPWV was analyzed as a continuous variable using its raw values (cm/s). In the binary logistic regression analysis, BAR was treated as a continuous variable and was transformed and analyzed in the form of natural logarithm because the raw data was skewed. Patients were grouped into tertiles on the basis of BAR. To evaluate trends, linear regression was applied to continuous variables, whereas chi-square trend tests were used for categorical variables. The assumption of linearity in the logit for these continuous variables in the logistic regression model was confirmed using Box-Tidwell test, while for continuous predictors in linear regression, it was confirmed using the Residuals vs. Fitted plot. Pearson or Spearman correlation coefficients were used to examine the relationships between baPWV and other indicators. The assessment of multicollinearity among the relative variables was conducted by calculating the Variance Inflation Factor (VIF), and none were found. A multivariable binary logistic regression model was used to compute odds ratios (ORs) and 95% confidence intervals (CIs) for assessing the independent effects of BAR on baPWV. The Receiver Operating Characteristic (ROC) curve analysis was employed to ascertain the optimal cut-off for the BAR in predicting increased arterial stiffness in individuals newly diagnosed with T2DM. Statistical analyses were performed using SPSS 27.0, and a bilateral p-value <0.05 was considered statistically significant.
3 Results
3.1 Baseline characteristics
The demographic and clinical characteristics of the enrolled patients are shown in Table 1. A total of 510 patients with newly diagnosed T2DM were included in this study. The average age of the patients was 45.66 ± 10.18 years. Among these patients, 402 (78.8%) were male and 98 (21.2%) were female. The mean baPWV was 1469.15 ± 295.82 cm/s, and 50.8% of patients exhibited arterial stiffness. The enrolled patients were categorized into three groups according to BAR level: T1, BAR <0.0874; T2, BAR between 0.0874 and 0.1161; and T3, BAR >0.1161. A higher BAR was associated with older age, higher blood creatinine and BUN, and lower BMI, eGFR and ALB. However, no significant differences were observed in sex, SBP, DBP, waist circumference, fasting blood glucose, HbA1c, fasting C-peptide, ALT, AST, GGT, serum uric acid, UACR, TG, TC, LDL-C or HDL-C levels. There were no statistically significant differences in smoking or alcohol consumption among the three groups. The higher BAR group had a greater baPWV. The percentage of patients with arterial stiffness in the T1, T2, and T3 subgroups were 40.6%, 52.4%, and 59.4%, respectively (p = 0.002), indicating an increase in the prevalence of arterial stiffness according to BAR subgroup.
Table 1
| Variables | ALL | T1 (n=170) | T2 (n=170) | T3 (n=170) | p-value |
|---|---|---|---|---|---|
| Sex (men) (case, %) | 402, 78.8% | 131, 77.1% | 132, 77.6% | 139, 81.1% | 0.512 |
| Age (years) | 45.66 ± 10.18 | 44.07 ± 10.24 | 45.44 ± 9.91 | 47.49 ± 10.17 | 0.008 |
| SBP (mmHg) | 123.50 ± 10.89 | 123.28 ± 10.36 | 123.36 ± 9.53 | 123.87 ± 12.60 | 0.865 |
| DBP (mmHg) | 79.11 ± 7.48 | 79.48 ± 7.15 | 79.21 ± 6.03 | 78.66 ± 8.98 | 0.597 |
| BMI (kg/m2) | 25.82 ± 4.41 | 26.60 ± 4.84 | 25.47 ± 4.21 | 25.38 ± 4.04 | 0.018 |
| Waist circumference (cm) | 91.83 ± 11.07 | 92.80 ± 11.64 | 91.25 ± 10.94 | 91.43 ± 10.59 | 0.382 |
| Fasting glucose (mmol/L) | 10.20 ± 3.93 | 9.92 ± 3.45 | 10.12 ± 4.27 | 10.57 ± 4.04 | 0.296 |
| HbA1c (%) | 11.90 ± 2.49 | 12.09 ± 2.50 | 11.74 ± 2.37 | 11.86 ± 2.58 | 0.434 |
| Fasting C-peptide (ng/ml) | 1.68 ± 1.24 | 1.67 ± 1.07 | 1.52 ± 0.93 | 1.84 ± 1.60 | 0.060 |
| ALT (U/L) (median (IQR)) | 20.00 (14.00-35.00) | 21.00 (14.00-39.00) | 21.00 (14.00-38.00) | 18.00 (13.00-31.00) | 0.080 |
| AST (U/L) (median (IQR)) | 17.00 (13.00-27.00) | 18.00 (14.00-31.00) | 18.00 (13.00-28.00) | 16.00 (13.00-23.25) | 0.089 |
| GGT (U/L) (median (IQR)) | 30.00 (19.00-54.60) | 32.50 (19.00-57.50) | 33.00 (19.25-62.00) | 29.00 (13.70-49.25) | 0.431 |
| ALB (g/L) | 39.98 ± 4.47 | 40.34 ± 5.14 | 40.51 ± 3.86 | 39.09 ± 4.20 | 0.006 |
| Uric acid (μmol/L) | 334.62 ± 113.50 | 337.90 ± 120.08 | 325.17 ± 100.01 | 340.88 ± 119.43 | 0.401 |
| Creatinine (μmol/L) (median (IQR)) | 64.90 (55.15-73.70) | 61.90 (53.55-69.30) | 65.35 (54.95-72.93) | 70.75 (57.76-81.10) | <0.001 |
| eGFR (ml/min/1.73m2) (median (IQR)) | 118.47 (103.08-137.48) | 125.12 (110.96-142.81) | 119.43 (103.23-138.72) | 109.62 (93.28-130.21) | <0.001 |
| BUN (mmol/L) | 4.27 ± 1.85 | 2.74 ± 0.64 | 4.07 ± 0.54 | 5.99 ± 2.08 | <0.001 |
| UACR (median (IQR)) | 4.84 (2.64-10.92) | 4.92 (2.48-10.91) | 4.94 (2.87-10.25) | 4.58 (2.72-12.15) | 0.855 |
| TG (mmol/L) (median (IQR)) | 1.60 (1.08-2.58) | 1.66 (1.08-2.99) | 1.58 (1.08-2.55) | 1.59 (1.06-2.49) | 0.694 |
| TC (mmol/L) | 4.82 ± 1.62 | 4.93 ± 1.43 | 4.64 ± 1.01 | 4.89 ± 2.20 | 0.215 |
| LDL-C (mmol/L) | 3.13 ± 0.93 | 3.17 ± 0.93 | 3.13 ± 0.95 | 3.07 ± 0.93 | 0.629 |
| HDL-C (mmol/L) | 1.00 ± 0.28 | 0.99 ± 0.29 | 0.98 ± 0.27 | 1.02 ± 0.28 | 0.477 |
| BAR | 0.11 ± 0.05 | 0.07 ± 0.01 | 0.10 ± 0.01 | 0.16 ± 0.07 | <0.001 |
| History of drinking | 0.447 | ||||
|  Never (case, %) | 341, 66.9% | 108, 63.5% | 114, 67.1% | 119, 70.0% | |
|  Current or ever (case, %) | 169, 33.1% | 62, 36.5% | 56, 32.9% | 51, 30.0% | |
| History of smoking | 0.662 | ||||
|  Never (case, %) | 322, 63.1% | 108, 63.5% | 103, 60.6% | 111, 65.3% | |
|  Current or ever (case, %) | 188, 36.9% | 62, 33.0% | 67, 35.6% | 59, 31.4% | |
| baPWV (cm/s) | 1469.15 ± 295.82 | 1406.42 ± 255.04 | 1462.12 ± 285.45 | 1538.92 ± 328.85 | <0.001 |
| Arterial stiffness, (case, %) | 259, 50.8% | 69, 40.6% | 89, 52.4% | 101, 59.4% | 0.002 |
Baseline characteristics of participants according to different BAR level groups.
SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; HbA1c, hemoglobin A1c; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transferase; ALB, albumin; BUN, blood urea nitrogen; UACR, urine albumin-to-creatinine ratio; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; BAR, blood urea nitrogen to serum albumin ratio; baPWV, brachial-ankle pulse wave velocity
3.2 Relationships between BAR and clinical indicators in patients with newly diagnosed with T2DM
As shown in Table 2, linear correlation analysis revealed that BAR was positively correlated with age (r = 0.222, p = 0.001), fasting C-peptide (r = 0.206, p < 0.001), creatinine (r = 0.615, p < 0.001), BUN (r = 0.950, p < 0.001), UACR (r = 0.362, p < 0.001 ) and baPWV (r = 0.226, p < 0.001) and negatively correlated with BMI (r = -0.089, p = 0.045), ALT (r = -0.091, p = 0.039), AST (r = -0.090, p = 0.042), ALB (r = -0.253, p < 0.001) and eGFR(r = -0.305, p < 0.001) in the total population. Among male patients, BAR was positively associated with age (r = 0.199, p < 0.001), fasting C-peptide (r = 0.189, p < 0.001), creatinine (r = 0.701, p = 0.006), BUN (r = 0.947, p < 0.001), UACR (r = 0.376, p < 0.001), HDL-C (r = 0.122, p = 0.016) and baPWV (r = 0.210, p < 0.001). However, it was negatively correlated with ALT (r = -0.110, p = 0.027), AST (r = -0.113, p = 0.023) and eGFR(r = -0.319, p < 0.001). In female patients, BAR was positively correlated with age (r = 0.371, p < 0.001), fasting C-peptide (r = 0.286, p = 0.003), creatinine (r = 0.280, p = 0.004), BUN (r = 0.937, p < 0.001) and baPWV (r = 0.334, p < 0.001), and negatively correlated with uric acid (r = 0.190, p = -0.049) and eGFR(r = -0.230, p = 0.017). Multifactorial stepwise linear regression analysis revealed a significant positive correlation between BAR and baPWV(β = 0.187, p < 0.001) after adjusting for relevant confounders (Table 3).
Table 2
| Variables | Whole | Male | Female | |||
|---|---|---|---|---|---|---|
| r | p-value | r | p-value | r | p-value | |
| Age | 0.222 | 0.001 | 0.199 | <0.001 | 0.371 | <0.001 |
| SBP | -0.009 | 0.884 | -0.019 | 0.712 | 0.018 | 0.857 |
| DBP | -0.049 | 0.275 | -0.010 | 0.849 | -0.180 | 0.062 |
| BMI | -0.089 | 0.045 | -0.083 | 0.097 | -0.122 | 0.211 |
| Waist circumference | -0.029 | 0.524 | -0.088 | 0.086 | 0.047 | 0.633 |
| Fasting glucose | 0.072 | 0.108 | 0.076 | 0.130 | 0.023 | 0.812 |
| HbA1c | -0.046 | 0.316 | -0.063 | 0.224 | 0.018 | 0.854 |
| Fasting C-peptide | 0.206 | <0.001 | 0.189 | <0.001 | 0.286 | 0.003 |
| ALT | -0.091 | 0.039 | -0.110 | 0.027 | -0.072 | 0.459 |
| AST | -0.090 | 0.042 | -0.113 | 0.023 | -0.048 | 0.619 |
| GGT | -0.041 | 0.361 | -0.093 | 0.065 | 0.052 | 0.597 |
| ALB | -0.253 | <0.001 | -0.283 | <0.001 | -0.165 | 0.088 |
| Uric acid | 0.036 | 0.423 | 0.083 | 0.096 | -0.190 | 0.049 |
| Creatinine | 0.615 | <0.001 | 0.701 | <0.001 | 0.280 | 0.004 |
| eGFR | -0.305 | <0.001 | -0.319 | <0.001 | -0.230 | 0.017 |
| BUN | 0.950 | <0.001 | 0.947 | <0.001 | 0.973 | <0.001 |
| UACR | 0.362 | <0.001 | 0.376 | <0.001 | 0.153 | 0.199 |
| TG | -0.031 | 0.489 | -0.080 | 0.112 | 0.093 | 0.342 |
| TC | -0.073 | 0.103 | -0.075 | 0.136 | -0.047 | 0.632 |
| LDL-C | -0.059 | 0.189 | -0.037 | 0.462 | -0.136 | 0.166 |
| HDL-C | 0.085 | 0.059 | 0.122 | 0.016 | 0.071 | 0.469 |
| baPWV | 0.226 | <0.001 | 0.210 | <0.001 | 0.334 | <0.001 |
Correlation analysis of relationship between lnBAR and characteristics in patients with type 2 diabetes.
SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; HbA1c, hemoglobin A1c; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transferase; ALB, albumin; BUN, blood urea nitrogen; UACR, urine albumin-to-creatinine ratio; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; BAR, blood urea nitrogen to serum albumin ratio; baPWV, brachial-ankle pulse wave velocity.
Table 3
| Variables | Unstandardized coefficients (95% CI) | Standardized coefficients | p-value |
|---|---|---|---|
| Age | 10.525 (8.109, 12.941) | 0.374 | <0.001 |
| SBP | 8.687 (6.498, 10.875) | 0.337 | <0.001 |
| HbA1c | -18.788 (-28.691, -8.884) | -0.163 | <0.001 |
| ALT | -0.835 (-1.552,-0.119) | -0.101 | 0.022 |
| BAR | 958.651 (518.429, 1398.874) | 0.187 | <0.001 |
Relationships between baPWV and various covariates including BAR, according to multiple stepwise linear regression analyses.
SBP, systolic blood pressure; HbA1c, hemoglobin A1c; UACR, urine albumin-to-creatinine ratio; BAR, blood urea nitrogen to serum albumin ratio.
3.3 Association of BAR with arterial stiffness in patients with newly diagnosed with T2DM
Arterial stiffness (baPWV ≥1400 cm/s) was assessed in relation to BAR using multivariable binary logistic regression analysis (Table 4). Three models were constructed to evaluate this association. As a continuous variable, each unit increase in the lnBAR was significantly associated with a greater risk of arterial stiffness (OR = 2.845, 95% CI: 1.745- 4.639, p < 0.001) in Model 1, with no adjustment for covariates. After adjusting for age and sex in Model 2, the lnBAR remained significantly associated with arterial stiffness (OR = 2.483, 95% CI: 1.484- 4.153, p = 0.001). After adjusting for age, sex, systolic blood pressure, diastolic blood pressure, BMI, WC, fasting glucose, fasting C-peptide, HbA1c, ALT, AST, GGT, creatinine, uric acid, TG, TC, HDL-C, and LDL-C, the associations between lnBAR and arterial stiffness remained significant (OR = 3.452, 95% CI: 1.586- 7.513, p = 0.002). When analyzed categorically, the T2 and T3 BAR groups presented a significantly greater risk of arterial stiffness than the T1 subgroup (T2: OR = 1.608, 95% CI: 1.047- 2.471, p = 0.030, T3: OR = 2.143, 95% CI: 1.390- 3.303, p = 0.001). In Model 2, the T3 subgroup had a greater risk than the T1 subgroup (OR = 1.914, 95% CI: 1.209- 3.029, p = 0.006). Following full adjustment, both the T2 (OR = 1.915, 95% CI: 1.106- 3.609, p = 0.044)) and T3 (OR = 2.064, 95% CI: 1.051- 4.054, p = 0.035) groups presented persistently elevated risks compared with the T1 group.
Table 4
| Variables | Model 1 OR (95%CI), p-value | Model 2 OR (95%CI), p-value | Model 3 OR (95%CI), p-value |
|---|---|---|---|
| baPWV (cm/s) | |||
| lnBAR | 2.845 (1.745, 4.639), <0.001 | 2.483 (1.484, 4.153), 0.001 | 3.452 (1.586, 7.513), 0.002 |
| BAR | |||
| T1 | Ref | Ref | Ref |
| T2 | 1.608 (1.047, 2.471), 0.030 | 1.553 (0.987, 2.443), 0.057 | 1.915 (1.016, 3.609), 0.044 |
| T3 | 2.143 (1.390, 3.303), 0.001 | 1.914 (1.209, 3.029), 0.006 | 2.064 (1.051, 4.054), 0.035 |
| p for trend | 0.015 | <0.001 | <0.001 |
Multivariable binary logistic regression for the association between BAR with arterial stiffness.
lnBAR, BAR levels were analyzed as naturally logarithmically transformed values.
BAR, blood urea nitrogen to serum albumin ratio; baPWV, brachial-ankle pulse wave velocity.
Model 1: unadjusted model.
Model 2: adjusted for age, sex.
Model 3: additionally adjusted for SBP, DBP, BMI, waist circumference, history of drinking, history of smoking, fasting glucose, fasting C-peptide, HbA1c, ALT, AST, GGT, Uric acid, UACR, eGFR, TG, TC, HDL-C, LDL-C.
3.4 Stratified analysis of BAR and arterial stiffness
The association between BAR and arterial stiffness was assessed by stratifying the covariates including age, sex, and BMI. The positive association between BAR and baPWV remained consistent when the data were divided into subgroups according to sex (male and female) and BMI (<25 kg/m² and ≥25 kg/m²)(p for interaction >0.05). An interaction effect for the association between BAR and baPWV was present between age groups, and the positive association between BAR and baPWV was found to be more significant in the <50 years subgroup than in the ≥50 years subgroup (Table 5).
Table 5
| Variables | Adjusted II OR(95%CI) | p-value | p for interaction |
|---|---|---|---|
| Stratified by Gender | 0.362 | ||
| Female | 20.007(1.421, 281.780) | 0.026 | |
| Male | 3.002(1.386, 6.503) | 0.005 | |
| Stratified by Age | 0.011 | ||
| <50 years | 3.402(1.378, 8.397) | 0.008 | |
| ≥50 years | 2.532(0.746, 8.598) | 0.136 | |
| Stratified by BMI | 0.495 | ||
| <25kg/m2 | 3.729(1.177, 11.810) | 0.025 | |
| ≥25kg/m2 | 3.212(1.218, 8.471) | 0.018 |
Stratified analysis of the association between BAR and arterial stiffness.
Adjusted for age, sex, SBP, DBP, BMI, waist circumference, history of drinking, history of smoking, fasting glucose, fasting C-peptide, HbA1c, ALT, AST, GGT, Uric acid, UACR, eGFR, TG, TC, HDL-C, LDL-C.
3.5 The cut-off BAR value to indicate arterial stiffness analyzed by ROC
The optimal cut-off value of BAR to predict increased arterial stiffness (defined as baPWV≥1400cm m/s) in newly diagnosed with T2DM was determined through ROC curve analysis. The value that maximized the Youden Index was selected as the optimal threshold. From our analysis of 510 patients, the optimal BAR cut-off was 0.1089, with an area under the curve (AUC) of 0.699(95% CI:0.654- 0.744), with a sensitivity of 70.3% and a specificity of 62.2% (Figure 1).
Figure 1
4 Discussion
In this study, we investigated the relationship between arterial stiffness, as quantified by baPWV and BAR, in patients newly diagnosed with T2DM. To our knowledge, this study is the first to identify a positive association between BAR and arterial stiffness in T2DM patients, even after adjusting for relevant potential confounders. In each subgroup, the positive association between BAR and baPWV was consistently maintained, as shown by further stratified analyses. Thus, these findings suggest that BAR may be useful in assessing early arterial stiffness in people with T2DM.
Research has consistently shown that there is a significant connection between arterial stiffness and atherosclerotic diseases, including myocardial infarction, heart failure, peripheral vascular disease, and stroke (–). Additionally, widespread cardiovascular risk factors such as diabetes, aging, hypertension, obesity, and chronic kidney disease can increase arterial stiffness and decrease elasticity (). Pulse wave velocity (PWV) is an important index for assessing arterial stiffness and can be characterized by carotid-femoral PWV (cfPWV), brachial-ankle PWV (baPWV), aortic PWV (aPWV), femoral-ankle PWV (faPWV), and carotid-radial PWV (crPWV) according to the pulse wave recording area. Compared with other parameters of arterial stiffness, such as the CAI, CAVI, and CAP, PWV is the most reliable indicator of CVD and is strongly correlated with CVD events and their risk factors, such as hypertension, obesity, and diabetes (, ). An increase in arterial stiffness is positively correlated with an increased risk of cardiovascular events and all-cause mortality among T2DM patients (). The baPWV is a clinically validated, simple, and cost-effective measure for evaluating arterial stiffness. Prospective clinical studies have demonstrated that arterial stiffness, quantified by baPWV, is a predictor of all-cause and cause-specific mortality in individuals with T2DM (, ). Research has indicated that an elevated baPWV acts as an independent predictor of adverse prognosis in individuals with ASCVD (). A 1-SD increase in baPWV raises the likelihood of cardiovascular events by 1.41 times (). An improvement in arterial stiffness was related to a 43% decrease in the risk of primary composite events, which included stroke, myocardial infarction, and all-cause mortality (). Research has further indicated that arterial stiffness is an independent risk factor for heart failure. Notably, for every 359 cm/s increase in baPWV, the risk of heart failure increases by 10% over an average period of 5.53 years (). Recent research has indicated a potential bidirectional connection between the onset of diabetes and arterial stiffness. The Chinese Kailuan Study cohort demonstrated that an increased baPWV significantly elevates the risk of developing diabetes, suggesting that arterial stiffness may act as an early pathological contributor to the development of the disease (). Further study suggested that aortic stiffness may impair glucose metabolic homeostasis through microvascular damage to the pancreas, liver, and skeletal muscle, potentially serving as an early predictive marker of diabetes (). Therefore, early assessment of arterial stiffness could be beneficial for predicting T2DM and diabetes-related macrovascular diseases. The identification of simple biomarkers to predict arterial stiffness in clinical settings remains a focal point of research in the field of metabolic diseases.
BUN and ALB are widely used biochemical markers that are easily accessible in routine clinical practice and offer a cost-effective means of assessment. Elevated BUN levels have been shown to be associated with a heightened risk of developing diabetes and its microvascular complications (, ), along with a positive, non-linear relationship with the risk of all-cause and cardiovascular mortality in individuals with T2DM (). Elderly patients with low ALB levels are more likely to have cardiovascular disease, and even those within low-normal ALB level may also be at higher risk of CVD and mortality (). BAR acts as an indicator of variations in BUN and ALB levels, offering insights into nutritional health, protein metabolism, and the function of the liver and kidney. It serves as an independent predictor of adverse prognosis and short-term mortality in various critical illnesses including pneumonia, sepsis, renal insufficiency, and CVD (–, –). Recent studies have identified BAR as a significant prognostic marker of chronic diseases. In a cohort of healthy individuals undergoing physical examinations, a significant positive correlation was identified between BAR and cerebral small vessel disease, including all its subtypes, in a dose-response relationship (). Moreover, a recent study has identified a significant positive correlation between elevated BAR and increased risks of CVD (OR 1.09), cardiovascular mortality (OR 1.13), and all-cause mortality (OR 1.12) in patients with diabetes (). In our study, 510 patients with newly diagnosed T2DM were stratified according to BAR tertiles. The group in the highest BAR group presented increased age, blood creatinine and BUN levels. Additionally, the highest BAR group had a greater proportion of patients with arterial stiffness than the other groups. Regardless of whether it was treated as a continuous or categorical variable, BAR was positively correlated with elevated baPWV after adjusting for relevant factors. These findings are consistent with the hypothesis that BAR may interact with various metabolic factors influencing cardiovascular disease and could be a useful marker for the early differentiation of patients with newly diagnosed T2DM with or without arterial stiffness. The stratified analyses indicated that the independent association between the BAR and elevated baPWV in different groups divided by sex and BMI remained consistent. Nevertheless, the limited sample size of the female group may result in imprecise estimated values. These results should be validated in larger, adequately powered studies. Stratified analysis also revealed that the association between BAR and baPWV was more significant in younger patients newly diagnosed with T2DM who were <50 years old. This finding suggests that BAR may be a more prominent correlation factor of arterial stiffness in younger patients with T2DM. Previous studies has been demonstrated that arterial stiffness is more readily improved in young individuals when a healthy lifestyle is adopted (). In contrast, arterial stiffness in older patients may be influenced by aging, multiple concurrent diseases, and other factors beyond liver and kidney function, thereby potentially explaining the observed attenuation of the association between BAR and baPWV in this subgroup.
The pathophysiological mechanisms connecting BAR and arterial stiffness in individuals with T2DM remain incompletely understood. Previous research has demonstrated a significant association between BAR and type 2 diabetic retinopathy, nephropathy, and macrovascular diseases (, , ). It was hypothesized that this association was attributable to the effects of the two principal components that constitute BAR. In the hyperglycemic state of T2DM, the body experiences hemodynamic abnormalities, renal function impairment, inflammation, oxidative stress, and endothelial dysfunction. These conditions lead to changes in BUN and ALB levels, promote arterial stiffness, and increase cardiovascular risk and adverse prognosis in patients with diabetes. First, BUN is a critical parameter for evaluating renal function. Elevated BUN levels signify increased protein catabolism and impaired renal function (). Arterial stiffness and chronic kidney disease may share common pathological pathways that facilitate their co-occurrence and progression (). The Framingham study established a significant correlation between PWV and the onset of proteinuria (). Early vascular dysfunction, indicated by a baPWV exceeding the 90th percentile, was significantly associated with proteinuria alone, impaired renal function alone, and the combined risk of proteinuria and renal dysfunction (). Second, existing research has demonstrated that inflammation is an important factor in the development of diabetes and its related complications (). Elevated BUN levels have been linked to inflammation, oxidative stress, and compromised endothelial function (, ). Urea can induce endoplasmic reticulum stress by inactivating the anti-atherogenic enzyme PGI2 synthase, thereby impairing endothelial function by inhibiting of cell proliferation and inducing endothelial-mesenchymal transition (, ). Additionally, urea induces the production of oxygen free radicals from endothelial progenitor cells (EPCs), leading to impaired EPCs function and the development of cardiovascular disease (). Plasma ALB fulfills several physiological functions, including reducing inflammation, preventing oxidative stress, preservation of vascular endothelial integrity. Research indicates that ALB can attenuate the expression of VCAM-1 induced by TNF-α, thereby inhibiting the onset of vascular inflammation (). Furthermore, ALB acts as a scavenger of oxygen-free radicals, inhibits the activity of angiotensin-converting enzymes, reduces the sensitivity of blood vessels to nitric oxide, and reduces apoptosis in endothelial cells (, ). Finally, elevated BUN levels may serve as indirect markers of a hypercoagulable state, thereby facilitating the onset of diabetic complications. Serum albumin also contributes to the stability of the circulatory system through its anticoagulant, antithrombotic, and antiplatelet aggregation properties ().
This study encountered various limitations. Firstly, the cross-sectional design of the study precludes the establishment of causal relationships between BAR and baPWV, and the possibility of reverse causality cannot be dismissed. Secondly, despite adjustments for multiple confounding variables, residual confounding, such as that related to lifestyle factors or unmeasured inflammatory markers, may persist. Thirdly, the single-center design and the homogeneous Chinese cohort limit the generalizability of the findings to other populations. Fourthly, the inclusion of only newly diagnosed T2DM patients may restrict the applicability of the results to individuals with a longer disease duration or those undergoing treatment. Finally, the absence of longitudinal data precludes the assessment of BAR’s predictive value for the progression of arterial stiffness. Consequently, it is essential to conduct more prospective randomized controlled trials to substantiate the conclusions of this study.
5 Conclusions
In conclusion, our findings indicate that BAR is positively and independently associated with arterial stiffness, as determined by baPWV, in Chinese patients with newly diagnosed T2DM. These results imply that BAR levels could play a role in improving the management of cardiovascular complications in patients with newly diagnosed T2DM, particularly those younger than 50 years.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving humans were approved by Ethics Committee of Longgang Central Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.
Author contributions
SH: Conceptualization, Formal Analysis, Methodology, Project administration, Writing – original draft, Writing – review & editing. WM: Conceptualization, Data curation, Writing – review & editing. MH: Data curation, Writing – review & editing, Investigation. QF: Methodology, Writing – review & editing, Investigation, Resources. JS: Writing – review & editing, Supervision.
Funding
The author(s) declare that no financial support was received for the research, and/or publication of this article.
Acknowledgments
We thank all of study participants involved in this study.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2025.1663831/full#supplementary-material
References
1
IDF global clinical practice recommendations for managing type 2 diabetes 2025. Diabetes Res Clin Pract. (2025) 224:112238. doi:Â 10.1016/j.diabres.2025.112238
2
LiYTengDShiXQinGQinYQuanHet al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. (2020) 369:m997. doi:Â 10.1136/bmj.m997
3
Dal CantoECerielloARydénLFerriniMHansenTBSchnellOet al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. (2019) 26:25–32. doi: 10.1177/2047487319878371
4
ChenCMLuCFLiuWSGongZHWangXQXuFet al. Association between fibrinogen/albumin ratio and arterial stiffness in patients with type 2 diabetes: A cross-sectional study. Front Pharmacol. (2022) 13:1120043. doi:Â 10.3389/fphar.2022.1120043
5
TąpolskaMSpałekMSzybowiczUDominROwsikKSochackaKet al. Arterial stiffness parameters correlate with estimated cardiovascular risk in humans: A clinical study. Int J Environ Res Public Health. (2019) 16:2547. doi: 10.3390/ijerph16142547
6
XuerebRAMagriCJXuerebRG. Arterial stiffness and its impact on cardiovascular health. Curr Cardiol Rep. (2023) 25:1337–49. doi: 10.1007/s11886-023-01951-1
7
Giraldo-GruesoMEcheverriD. From endothelial dysfunction to arterial stiffness in diabetes mellitus. Curr Diabetes Rev. (2020) 16:230–7. doi: 10.2174/1573399814666181017120415
8
MaedaYInoguchiTEtohEKodamaYSasakiSSonodaNet al. Brachial-ankle pulse wave velocity predicts all-cause mortality and cardiovascular events in patients with diabetes: the Kyushu Prevention Study of Atherosclerosis. Diabetes Care. (2014) 37:2383–90. doi: 10.2337/dc13-1886
9
KimHLJeonWKJohHSLimWHSeoJBKimSHet al. Brachial-ankle pulse wave velocity as a predictor of long-term cardiovascular events in 2174 subjects with type 2 diabetes mellitus: A retrospective cohort study. Med (Baltimore). (2022) 101:e31758. doi:Â 10.1097/MD.0000000000031758
10
ShenJWangZLiuYWangTWangXYQuXHet al. Association of blood urea nitrogen with all-cause and cardiovascular mortality in hyperlipidemia: NHANES 1999-2018. Lipids Health Dis. (2024) 23:164. doi:Â 10.1186/s12944-024-02158-1
11
LiuHXinXGanJHuangJ. The long-term effects of blood urea nitrogen levels on cardiovascular disease and all-cause mortality in diabetes: a prospective cohort study. BMC Cardiovasc Disord. (2024) 24:256. doi:Â 10.1186/s12872-024-03928-6
12
SunLYinHLiuMXuGZhouXGePet al. Impaired albumin function: a novel potential indicator for liver function damage. Ann Med. (2019) 51:333–44. doi: 10.1080/07853890.2019.1693056
13
TavernaMMarieALMiraJPGuidetB. Specific antioxidant properties of human serum albumin. Ann Intensive Care. (2013) 3:4. doi:Â 10.1186/2110-5820-3-4
14
AgarwalMJoshiMGuptaMBhartiNChakrabortiASonigraM. Role of blood urea nitrogen and serum albumin ratio in predicting severity of community acquired pneumonia (CAP). Monaldi Arch Chest Dis. (2021) 92:3. doi:Â 10.4081/monaldi.2021.2091
15
ZhaoLLiuYTanZZhangMLiSLuoGet al. The prognostic value of blood urea nitrogen to albumin ratio on patients with heart failure. Int Heart J. (2023) 64:1010–7. doi: 10.1536/ihj.23-383
16
MinJLuJZhongLYuanMXuY. The correlation study between blood urea nitrogen to serum albumin ratio and prognosis of patients with sepsis during hospitalization. BMC Anesthesiol. (2022) 22:404. doi:Â 10.1186/s12871-022-01947-4
17
LiuSQiuCLiWLiXLiuFHuG. Blood urea nitrogen to serum albumin ratio as a new prognostic indicator in type 2 diabetes mellitus patients with chronic kidney disease. Sci Rep. (2024) 14:8002. doi:Â 10.1038/s41598-024-58678-4
18
GuXZhaoLZhuJGuHLiHWangLet al. Serum mimecan is associated with arterial stiffness in hypertensive patients. J Am Heart Assoc. (2015) 4:e002010. doi:Â 10.1161/JAHA.115.002010
19
ZhaoLZhouXChenYDongQZhengQWangYet al. Association of visceral fat area or BMI with arterial stiffness in ideal cardiovascular health metrics among T2DM patients. J Diabetes. (2024) 16:e13463. doi:Â 10.1111/1753-0407.13463
20
ZhengHWuSLiuXQiuGChenSWuYet al. Association between arterial stiffness and new-onset heart failure: the kailuan study. Arterioscler Thromb Vasc Biol. (2023) 43:e104–104e111. doi: 10.1161/ATVBAHA.122.317715
21
MiyagiTIshidaAShinzatoTOhyaY. Arterial stiffness is associated with small vessel disease irrespective of blood pressure in stroke-free individuals. Stroke. (2023) 54:2814–21. doi: 10.1161/STROKEAHA.123.042512
22
EcobiciMVoiculescuM. Importance of arterial stiffness in predicting cardiovascular events. Rom J Intern Med. (2017) 55:8–13. doi: 10.1515/rjim-2016-0043
23
InserraFForcadaPCastellaroACastellaroC. Chronic kidney disease and arterial stiffness: A two-way path. Front Med (Lausanne). (2021) 8:765924. doi:Â 10.3389/fmed.2021.765924
24
DarroudiSEslamiyehMMansooriANazarEAlinezhad-NamaghiMRezvaniRet al. Multivariate linear regression to predict association of non-invasive arterial stiffness with cardiovascular events. ESC Heart Fail. (2025) 12:1141–50. doi: 10.1002/ehf2.15077
25
SharifSVisserenFSpieringWde JongPABotsMLWesterinkJet al. Arterial stiffness as a risk factor for cardiovascular events and all-cause mortality in people with Type 2 diabetes. Diabetes Med. (2019) 36:1125–32. doi: 10.1111/dme.13954
26
KimJMKimSSKimIJKimJHKimBHKimMKet al. Arterial stiffness is an independent predictor for risk of mortality in patients with type 2 diabetes mellitus: the REBOUND study. Cardiovasc Diabetol. (2020) 19:143. doi:Â 10.1186/s12933-020-01120-6
27
SangTLvNDangAChengNZhangW. Brachial-ankle pulse wave velocity and prognosis in patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Hypertens Res. (2021) 44:1175–85. doi: 10.1038/s41440-021-00678-2
28
ZuoYChenSTianXWuSWangA. Changes in baPWV and the risk of clinical outcomes: a cohort study of Chinese community-based population. J Hum Hypertens. (2024) 38:460–6. doi: 10.1038/s41371-024-00902-9
29
ZhengMZhangXChenSSongYZhaoQGaoXet al. Arterial stiffness preceding diabetes: A longitudinal study. Circ Res. (2020) 127:1491–8. doi: 10.1161/CIRCRESAHA.120.317950
30
CohenJBMitchellGFGillDBurgessSRahmanMHanffTCet al. Arterial stiffness and diabetes risk in framingham heart study and UK biobank. Circ Res. (2022) 131:545–54. doi: 10.1161/CIRCRESAHA.122.320796
31
LiSNCuiYFLuoZYLouYMLiaoMQChenHEet al. Association between blood urea nitrogen and incidence of type 2 diabetes mellitus in a Chinese population: a cohort study. Endocr J. (2021) 68:1057–65. doi: 10.1507/endocrj.EJ20-0794
32
WangRXuYXXuFWangCHZhaoLHWangLHet al. Increased blood urea nitrogen levels and compromised peripheral nerve function in patients with type 2 diabetes. World J Diabetes. (2025) 16:101966. doi:Â 10.4239/wjd.v16.i4.101966
33
SchalkBWVisserMBremmerMAPenninxBWBouterLMDeegDJ. Change of serum albumin and risk of cardiovascular disease and all-cause mortality: Longitudinal Aging Study Amsterdam. Am J Epidemiol. (2006) 164:969–77. doi: 10.1093/aje/kwj312
34
WangYQinLHZhangKZhangDWWangWJXuAMet al. Blood urea nitrogen to albumin ratio is a novel predictor of fatal outcome for patients with severe fever with thrombocytopenia syndrome. J Med Virol. (2024) 96:e29731. doi:Â 10.1002/jmv.29731
35
WuQZhengJLinJXieLTangMKeMet al. Preoperative blood urea nitrogen-to-serum albumin ratio for prediction of in-hospital mortality in patients who underwent emergency surgery for acute type A aortic dissection. Hypertens Res. (2024) 47:1934–42. doi: 10.1038/s41440-024-01673-z
36
ZengZKeXGongSHuangXLiuQHuangXet al. Blood urea nitrogen to serum albumin ratio: a good predictor of in-hospital and 90-day all-cause mortality in patients with acute exacerbations of chronic obstructive pulmonary disease. BMC Pulm Med. (2022) 22:476. doi:Â 10.1186/s12890-022-02258-7
37
NamKWKwonHMJeongHYParkJHMinK. Blood urea nitrogen to albumin ratio is associated with cerebral small vessel diseases. Sci Rep. (2024) 14:4455. doi:Â 10.1038/s41598-024-54919-8
38
ZhuHXieWWangPJiangSHuaYShaoGet al. The relationship between blood urea nitrogen to serum albumin ratio and cardiovascular diseases, cardiovascular mortality, and all-cause mortality in patients with diabetes mellitus. Front Endocrinol (Lausanne). (2025) 16:1456731. doi:Â 10.3389/fendo.2025.1456731
39
DaiFFPanJDHeXJ. Association between blood urea nitrogen to albumin ratio and diabetic retinopathy: insights from the US National Health and Nutrition Examination Survey. Int J Ophthalmol. (2025) 18:1097–104. doi: 10.18240/ijo.2025.06.17
40
MacedoE. Blood urea nitrogen beyond estimation of renal function. Crit Care Med. (2011) 39:405–6. doi: 10.1097/CCM.0b013e318205c33a
41
UpadhyayAHwangSJMitchellGFVasanRSVitaJAStantchevPIet al. Arterial stiffness in mild-to-moderate CKD. J Am Soc Nephrol. (2009) 20:2044–53. doi: 10.1681/ASN.2009010074
42
LiJGaoJZhangXCuiLHouJGaoBet al. The relationship between vascular aging phenotypes and renal damage among individuals with type 2 diabetes. Cardiorenal Med. (2023) 13:91–100. doi: 10.1159/000526345
43
GuoCCaiQLiYLiFLiuK. A cross-sectional National Health and Nutrition Examination survey-based study of the association between systemic immune-inflammation index and blood urea nitrogen levels in United States adolescents. Sci Rep. (2024) 14:13248. doi:Â 10.1038/s41598-024-64073-w
44
BosevskiMSoedamah-MuthuSS. Blood urea level and diabetes duration are independently associated with ankle-brachial index in type 2 diabetic patients. Diabetes Metab Syndr. (2012) 6:32–5. doi: 10.1016/j.dsx.2012.05.006
45
D’ApolitoMDuXPisanelliDPettoello-MantovaniMCampanozziAGiaccoFet al. Urea-induced ROS cause endothelial dysfunction in chronic renal failure. Atherosclerosis. (2015) 239:393–400. doi: 10.1016/j.atherosclerosis.2015.01.034
46
ColomboGAltomareAAstoriELandoniLGaravagliaMLRossiRet al. Effects of physiological and pathological urea concentrations on human microvascular endothelial cells. Int J Mol Sci. (2022) 24:691. doi:Â 10.3390/ijms24010691
47
D’ApolitoMColiaALLasalviaMCapozziVFalconeMPPettoello-MantovaniMet al. Urea-induced ROS accelerate senescence in endothelial progenitor cells. Atherosclerosis. (2017) 263:127–36. doi: 10.1016/j.atherosclerosis.2017.06.028
48
ZhangWJFreiB. Albumin selectively inhibits TNF alpha-induced expression of vascular cell adhesion molecule-1 in human aortic endothelial cells. Cardiovasc Res. (2002) 55:820–9. doi: 10.1016/s0008-6363(02)00492-3
49
BihariSBannard-SmithJBellomoR. Albumin as a drug: its biological effects beyond volume expansion. Crit Care Resusc. (2020) 22:257–65. doi: 10.1016/S1441-2772(23)00394-0
50
BeversLMvan FaassenEEVuongTDNiZBoerPKoomansHAet al. Low albumin levels increase endothelial NO production and decrease vascular NO sensitivity. Nephrol Dial Transplant. (2006) 21:3443–9. doi: 10.1093/ndt/gfl443
51
ManolisAAManolisTAMelitaHMikhailidisDPManolisAS. Low serum albumin: A neglected predictor in patients with cardiovascular disease. Eur J Intern Med. (2022) 102:24–39. doi: 10.1016/j.ejim.2022.05.004
Summary
Keywords
type 2 diabetes mellitus, arterial stiffness, blood urea nitrogen to serum albumin ratio, brachial-ankle pulse wave velocity, cardiovascular disease
Citation
He S, Meng W, Huang M, Fu Q and Shen J (2025) Association of blood urea nitrogen to serum albumin ratio with arterial stiffness in type 2 diabetes patients: a Chinese cross-sectional study. Front. Endocrinol. 16:1663831. doi: 10.3389/fendo.2025.1663831
Received
11 July 2025
Accepted
25 September 2025
Published
08 October 2025
Volume
16 - 2025
Edited by
Gaetano Santulli, Albert Einstein College of Medicine, United States
Reviewed by
Zeshan Ali, Bohai University, China
Kusum Devi, The University of Iowa, United States
Varun Kashyap, Indian Council of Medical Research (ICMR), India
Updates
Copyright
© 2025 He, Meng, Huang, Fu and Shen.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jie Shen, sjiesy@smu.edu.cn
†ORCID: Jie Shen, orcid.org/0000-0001-6952-9541
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.